Malabsorption Syndrome Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Malabsorption Syndrome Market is segmented By Product Type (Celiac Disease, Lactose Intolerance, Crohns Disease, Tropical Sprue, Short Bowel Syndrome), By Diagnosis (Blood Tests , Endoscopy and Biopsy, Imaging Tests , Hydrogen Breath Test), By treatment (Gluten-free diet, Anti-inflammatory drugs, Antibiotics, Nutritional supplements, Protease and lipase supplements, Antidiarrheal agents, Others), By end user (Hospitals, Academic and Research, Institutes, Pharmaceutical companies, Nutrition Clinics, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Malabsorption Syndrome Market Size
Market Size in USD
CAGR6.8%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.8% |
| Market Concentration | High |
| Major Players | AbbVie Inc., ImmunogenX, LLC, AstraZeneca, ImmusanT, Inc., Ritter Pharmaceuticals |
please let us know !
Malabsorption Syndrome Market Analysis
The Global Malabsorption Syndrome Market is estimated to be valued at USD 3.42 Billion in 2024 and is expected to reach USD 5.41 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
The market has been witnessing positive trends over the past few years due rise in cases of celiac disease, Crohn's disease, and small intestine bacterial overgrowth. Adoption of advanced diagnostic techniques such as magnetic resonance imaging (MRI) enterography and capsule endoscopy has resulted in accurate detection of malabsorption syndrome. Furthermore, availability of novel drug formulations with improved absorption and targeted drug delivery systems is also driving the market. However, lack of awareness about malabsorption syndrome, especially in developing regions, poses a major challenge for market growth during the forecast period.